


TSE : 4568

Reference Data

(Consolidated Financial Results for Q1 FY2009)



Daiichi-Sankyo

July 31, 2009

Daiichi Sankyo Co., Ltd.
<http://www.daiichisankyo.com>

(This page is intentionally left blank)

Reference Data

(Consolidated Financial Results for Q1 FY2009)

[1] Summary of Income Statement	P1, 2
[2] Currency Rate	P3
[3] Sales of Global Products	P3
[4] Overseas Sales	P4
[5] Consolidated Segment Information – Operating Segment	P5
[6] Consolidated Segment Information – Geographic Segment	P5
[7] Status of Major Companies	P6 ~ 9
[8] Number of Employees	P10
[9] Consolidated Balance Sheets	P11, 12
[10] Consolidated Statements of Cash Flows	P13
[11] R&D Pipeline	P14, 15

<Historical Data>

Each numerical value regarding the future prospect in this material is derived from our judgment and assumptions based on the currently available information and may include risk and uncertainty. For this reason, the actual performance data, etc. may differ from the prospective value.

1. Summary of Income Statement

< Daiichi Sankyo Group - Consolidated > (Billions of yen)

	FY2009 Results				Details (YoY Changes)
	Q1	Progress	YoY Changes		
Net Sales	<11.5> 100.0	227.1	48.8%	23.4	- Consolidation of Ranbaxy: +29.7 - Azor (lump sum payment received) in FY2008: -4.7 - Decrease by yen appreciation: -8.0 - Increase of Olmesartan sales: <u>+5.3</u> , Decrease of Levofloxacin sales: <u>-6.0</u> [Underlined figures include loss from currency fluctuation]
Cost of Sales	27.5	62.5	46.3%	13.9	- Cost to sales ratio: +3.6Points Impact of consolidation of Ranbaxy: +4.5Points
SG&A expenses	60.7	137.8	47.7%	22.8	
R&D expenses	19.9	45.1	48.5%	8.2	- Consolidation of Ranbaxy: +2.1 - Increase in development costs of Edoxaban (DU-176b)
Other expenses	40.8	92.7	47.3%	14.6	- Consolidation of Ranbaxy: +12.3 - Increase in amortization costs related to Ranbaxy and U3 Pharma: +2.8
Operating income	<-33.1> 11.8	26.8	65.3%	-13.2	
Non-operating income		3.9	96.8%	0.2	
Non-operating expenses		23.5	293.4%	20.7	- Consolidation of Ranbaxy: +22.7
Ordinary income	<-82.5> 3.2	7.2	19.4%	-33.7	
Extraordinary gains		2.1		2.1	- Gain on sales of investment securities: +1.8
Extraordinary losses		0.7		-0.7	
Income before income taxes and minority interests	3.8	8.6	23.3%	-30.9	
Net Income	<> -	-6.4	-	-31.5	- Income taxes: 24.0 (Tax rate 277.7%) [Factors leading to increase in tax rate] Prior-year tax revision: 7.5 Consolidation adjustment of Ranbaxy (non-application of tax effect accounting): 7.0 Non-application of R&D tax credits on parent - Minority interests in loss: -8.9

< Ranbaxy >

	FY2009 Results			FY2009 Forecasts	
	Q1	Progress	YoY Changes	Full Year	YoY Changes
Net Sales	<> 100.0	29.7		135.0	
Cost of Sales	57.7	17.1			
SG&A expenses	48.4	14.4			
R&D expenses	7.1	2.1			
Other expenses	41.3	12.3			
Operating income	<> -	-1.8			
Non-operating income		1.0			
Non-operating expenses		22.7			
Ordinary income	<> -	-23.5			
Extraordinary gains		0.0			
Extraordinary losses		0.0			
Income before income taxes and minority interests	-	-23.5			
Net Income	<> -	-16.9		-19.0	

< Impact of Business Combination of Ranbaxy >

FY2009 Results	
Q1	YoY Changes
1.5	1.5
1.5	1.5
-1.5	-1.5
-1.5	-1.5
-1.5	-1.5
0.5	0.5

Revisions made on 1st half forecasts. Full year forecasts remain unchanged.

(Billions of yen)

FY2009 Forecasts

1st half		From May Forecast	YoY Changes	Full Year		YoY Changes
<14.4>				<14.0>		
100.0	465.0		58.7	100.0	960.0	117.9
29.0	135.0		37.4	29.0	278.0	63.6
62.2	289.0		41.9	61.0	586.0	47.1
20.0	93.0		10.7	20.2	194.0	9.5
42.2	196.0		31.3	40.8	392.0	37.7
<-33.5>				<8.0>		
8.8	41.0		-20.6	10.0	96.0	7.1
	4.0	-1.0	-2.1		6.0	-6.3
	8.0	-21.0	-0.1		33.0	-13.0
<-38.0>				<25.1>		
8.0	37.0	20.0	-22.6	7.2	69.0	13.8
	0.0		-0.8		0.0	-3.8
	0.0		-3.9		0.0	-367.2
8.0	37.0	20.0	-19.6	7.2	69.0	377.3
<-67.6>				<>		
2.4	11.0	3.0	-23.0	4.2	40.0	255.5

< Daiichi Sankyo's Performance excluding the impact of Ranbaxy's Consolidation >

(Billions of yen)

FY2009 Results

Q1		YoY Changes
<-3.1>		
100.0	197.4	-6.3
23.0	45.4	-3.6
61.8	122.0	6.9
21.8	43.0	6.1
40.0	79.0	0.8
<-24.9>		
15.2	30.0	-10.0
	2.9	-0.7
	0.8	-2.0
<-21.3>		
16.3	32.2	-8.7
	2.1	2.1
	0.7	-0.7
17.0	33.6	-5.9
<-60.1>		
5.1	10.0	-15.1

2. Currency Rate

	FY2008	FY2009	FY2009 Forecast	
	Q1 Result	Q1 Result	Full Year	Annual impact of one yen change in currency rate
Yen / USD (average)	104.6	97.3	95.0	Net Sales ¥2.3 billion Operating Income ¥0.3 billion
Yen / EUR (average)	163.4	132.6	120.0	Net Sales ¥0.6 billion Operating Income -
Yen / INR (average)	-	1.89	1.90	Net Sales* ¥7.0 billion

* Annual impact of 0.1 yen change in currency rate for Indian Rupees

3. Sales of Global Products

	FY2009 Results				(Billions of yen)	
	Q1	Progress	YoY Changes	FY2009 Forecast		
				1st half	Full Year	
Olmesartan <antihypertensive>	<10.5>			<7.3>	<11.5>	
	56.0	49.9%	5.3	112.2	235.5	
Olmetec (JPN)	<22.1>	19.0	48.8%	3.4	<24.6> <27.4>	
Benicar HCT / Benicar (US)	<-5.6>	22.1	51.9%	-1.3	<-6.5> <-1.6>	
Azor (US)	<121.5>	3.0	46.7%	1.7	<71.7> <72.9>	
Olmetec Plus / Olmetec (EU)	<-0.2>	8.3	48.8%	0.0	<-8.9> <-2.7>	
Sevikar (EU)	<->	0.9	41.1%	0.9	<-> <105.6>	
Other subsidiaries / Export, etc.	<29.9>	2.6	52.8%	0.6	<-7.0> <4.3>	
Levofloxacin <synthetic antibacterial>	<-23.2>	19.8	46.4%	-6.0	<-13.4> <-5.8>	
	42.7	92.0				
Cravit (JPN)	<-6.8>	9.5	45.3%	-0.7	<7.1> <2.3>	
Export, etc	<-49.6>	4.8	43.8%	-4.7	<-38.3> <-17.9>	
Royalty	<-9.9>	3.7	52.4%	-0.4	<-13.0> <-6.7>	
Other subsidiaries	<-6.4>	1.8	48.7%	-0.1	<-4.2> <-0.2>	
Pravastatin <antihyperlipidemic>	<-8.5>	14.7	50.7%	-1.4	<-9.2> <-9.6>	
	29.0	55.0				
Mevalotin (JPN)	<-8.3>	12.4	49.7%	-1.1	<-6.1> <-7.3>	
Export, etc	<-37.6>	0.7	65.4%	-0.4	<-45.2> <-37.0>	
European Subsidiaries	<11.3>	0.8	54.2%	0.1	<-24.0> <-37.0>	
Other subsidiaries	<7.7>	0.8	54.7%	0.1	<-1.2> <17.9>	
Prasugrel (alliance revenue) <antiplatelet>	<->	0.0	-	0.0		
Efient (EU)	<->	0.0	-	0.0		

Forecast of prasugrel is not disclosed.

Alliance Revenue of Efient (EU) is booked on Daiichi Sankyo Co., Ltd.

4. Overseas Sales

Consolidated basis			(Billions of yen)	
	FY2009 Results		FY2009 Forecast	
	Q1	YoY Changes	Full Year	YoY Changes
Overseas sales	<23.9> 109.8	21.2	<24.7> 465.5	92.2
Overseas sales ratio	48.4%		48.5%	
North America	<1.1> 58.9	0.6		
Europe	<21.3> 27.2	4.8		
Other	<197.4> 23.7	15.7		

Overseas sales of Ranbaxy			(Billions of yen)	
	FY2009 Results		FY2009 Forecast	
	Q1	YoY Changes	Full Year	YoY Changes
Overseas sales	<-> 29.6	29.6	135.0	
North America	<-> 7.9	7.9		
Europe	<-> 5.7	5.7		
Other	<-> 16.0	16.0		

Overseas sales excluding Ranbaxy			(Billions of yen)	
	FY2009 Results		FY2009 Forecast	
	Q1	YoY Changes	Full Year	YoY Changes
Overseas sales	<-9.5> 80.2	-8.4	<-1.2> 330.5	-4.2
Overseas sales ratio	40.6%		40.1%	
North America	<-12.5> 51.0	-7.3	<0.5> 212.0	1.1
Europe	<-3.9> 21.5	-0.9	<-6.6> 84.0	-6.0
Other	<-3.4> 7.7	-0.3	<2.2> 34.5	0.7

5. Consolidated Segment information - Operating Segment

(Billions of yen)

	FY2008 Results			FY2009 Results	
	Q1	1st half	Full Year	Q1	YoY Changes
Net Sales	<-13.5> 203.7	<-8.4> 406.3	<-4.3> 842.1	<-11.5> 227.1	23.4
Pharmaceuticals	<-10.2> 202.9	<-4.6> 404.5	<-0.2> 838.7	<-11.5> 226.3	23.4
Domestic	<-8.2> 103.3	<-4.5> 205.0	<-4.7> 416.7	<-3.1> 106.6	3.2
Overseas *	<-14.1> 88.7	<-5.5> 174.5	<-5.9> 373.3	<-23.9> 109.9	21.2
OTC drugs	<-3.1> 10.2	<-1.8> 24.0	<-6.2> 47.2	<-6.9> 9.5	-0.7
Other	<-91.5> 0.8	<-90.7> 1.8	<-91.3> 3.4	<-2.6> 0.8	0.0
Operating income	<-41.0> 40.0	<-34.4> 61.6	<-43.7> 88.3	<-33.1> 26.8	-13.2
Pharmaceuticals	<-42.3> 39.4	<-35.9> 60.4	<-44.7> 86.1	<-33.5> 26.2	-13.2
Other	<-> 0.5	<-> 1.2	<-116.2> 2.2	<-1.3> 0.5	0.0

* The accounting period of Daiichi Sankyo Europe GmbH (DSE) in FY2007 was 15 months following a change in its fiscal year-end from December to March. The operating results of DSE for the period from January to March 2007 was net sales of ¥14.1 billion and operating income of ¥1.8 billion.

6. Consolidated Segment information - Geographic Segment

(Billions of yen)

	FY2008 Results			FY2009 Results	
	Q1	1st half	Full Year	Q1	YoY Changes
Net Sales	<-13.5> 100.0 203.7	<-8.4> 100.0 406.3	<-4.3> 100.0 842.1	<-11.5> 100.0 227.1	23.4
Japan	<-12.6> 65.1 132.7	<-10.1> 65.4 265.7	<-11.4> 62.9 529.8	<-3.1> 56.6 128.5	-4.2
North America	<-12.5> 24.9 50.7	<-6.9> 23.6 95.9	<-7.2> 22.7 190.8	<-7.0> 23.9 54.2	3.6
Europe *	<-53.1> 7.4 15.2	<-25.8> 8.3 33.6	<-0.7> 9.2 77.4	<-48.1> 9.9 22.5	7.3
India			<-> 1.8 15.3	<-> 5.1 11.5	11.5
Other	<-16.9> 2.6 5.2	<-16.6> 2.7 11.1	<-10.9> 3.4 28.9	<-99.7> 4.6 10.5	5.2
Operating income	<-41.0> 40.0	<-34.4> 61.6	<-43.7> 88.3	<-33.1> 26.8	-13.2
Japan	18.5	26.7	42.9	15.6	
North America	16.9	27.8	50.3	13.9	
Europe *	1.2	1.3	5.8	1.2	
India			-18.9	-3.2	
Other	0.7	1.1	0.4	0.9	

* The accounting period of Daiichi Sankyo Europe GmbH (DSE) in FY2007 was 15 months following a change in its fiscal year-end from December to March. The operating results of DSE for the period from January to March 2007 was net sales of ¥14.1 billion and operating income of ¥1.8 billion.

7. Status of Major Companies

7-1. Daiichi Sankyo Co., Ltd.

(Billions of yen)

	FY2009 Results			FY2009 Forecast	
	Q1	Progress	YoY Changes	1st half	Full Year
Total net sales of ethical pharmaceuticals	<3.7> 104.6	50.1%	3.7	<4.3> 209.0	<5.7> 430.0
Cardiovascular disease	<3.8> 62.3	49.4%	2.3	<7.5> 126.0	<9.2> 254.0
Olmetec <antihypertensive>	<22.1> 19.0	48.8%	3.4	<24.6> 39.0	<27.4> 82.0
Calblock <antihypertensive>	<14.5> 3.5	49.3%	0.4	<17.4> 7.0	<23.6> 15.0
Artist <antihypertensive>	<6.3> 6.0	50.3%	0.4	<9.2> 12.0	<9.5> 24.0
Mevalotin <antihyperlipidemic agent>	<-8.3> 12.4	49.7%	-1.1	<-6.1> 25.0	<-7.3> 47.0
Kremezin <treatment for chronic renal failure>	<5.5> 3.4	47.9%	0.2	<9.3> 7.0	<9.8> 14.0
Hanp <treatment for acute cardiac failure>	<1.5> 2.4	60.9%	0.0	<-5.7> 4.0	<-1.8> 9.0
Livalo <antihyperlipidemic agent>	<22.8> 1.8	45.6%	0.3	<36.0> 4.0	<39.4> 8.5
Sunrhythm <antiarrhythmic agent>	<-1.2> 3.0	50.6%	0.0	<1.0> 6.0	<3.0> 12.0
Fastic <antidiabetic agent>	<1.8> 1.4	45.1%	0.0	<14.8> 3.0	<17.2> 6.0
Infectious diseases/bone and joint diseases/ immunological allergic diseases/urology	<9.4> 33.7	47.5%	2.9	<13.2> 71.0	<12.8> 155.0
Cravit <synthetic antibacterial agent>	<-6.8> 9.5	45.3%	-0.7	<7.1> 21.0	<2.3> 44.0
Loxonin <anti-inflammatory analgesic>	<33.0> 11.2	46.8%	2.8	<27.2> 24.0	<31.8> 51.0
Mobic <anti-inflammatory analgesic>	<-17.5> 2.0	44.8%	-0.4	<-1.9> 4.5	<12.8> 9.5
Urief <treatment for dysuria>	<26.6> 2.2	49.5%	0.5	<27.2> 4.5	<26.4> 10.0
Zyrtec <antiallergic agent>	<18.4> 2.4	60.0%	0.4	<11.5> 4.0	<7.4> 10.0
Contrast agents / cancer / gastric diseases	<2.9> 12.6	50.5%	0.4	<0.9> 25.0	<0.4> 49.0
Omnipaque <contrast agent>	<-2.0> 7.1	49.3%	-0.1	<-0.5> 14.5	<-1.1> 28.0
Topotecin <anticancer agent>	<5.6> 1.7	53.3%	0.1	<1.8> 3.2	<4.4> 6.5

7-2. Daiichi Sankyo Healthcare Co., Ltd

	FY2009 Results			FY2009 Forecast		
	Q1	Progress	YoY Changes	1st half	Full Year	
Daiichi Sankyo Healthcare Co., Ltd	<-6.9>	9.5	38.9%	-0.7	<-2.1>	<-5.9>
				24.5	50.0	
LuLu Series	<-2.4>	1.2	22.8%	0.0	<-9.8>	<-12.6>
				5.3	11.0	
Gaster 10	<-29.1>	0.5	37.3%	-0.2	<-15.3>	<-14.0>
				1.4	2.8	
Shin-Sankyo Ichoyaku series	<26.3>	0.9	51.5%	0.2	<-5.8>	<-8.5>
				1.7	3.6	
Patecs series	<15.3>	0.9	43.0%	0.1	<-33.6>	<-27.7>
				2.1	3.4	
Transino	<-62.3>	0.3	26.2%	-0.4	<-20.0>	<-9.9>
				1.0	1.7	

7-3. Daiichi Sankyo, Inc. (US)

	FY2009 Results			FY2009 Forecast		
	Q1	Progress	YoY Changes	1st half	Full Year	
Daiichi Sankyo, Inc. (DSI)	<-11.2>	33.0	49.3%	-4.2	<-2.7>	<-8.3>
mil USD	<-4.6>	339	48.1%	-16	<-8.7>	<-14.6>
				705	1,474	
Benicar / Benicar HCT <antihypertensive>	<-5.6>	22.1	51.9%	-1.3	<-6.5>	<-1.6>
				42.5	86.0	
mil USD	<1.4>	227	50.7%	3	<4.4>	<4.2>
				447	905	
Azor <antihypertensive>	<121.5>	3.0	46.7%	1.7	<71.7>	<72.9>
				6.5	15.0	
mil USD	<138.0>	31	45.6%	18	<91.8>	<82.9>
				68	158	
Welchol <antihyperlipidemic / type 2 diabetes>	<7.0>	6.9	51.0%	0.5	<7.8>	<16.4>
				13.5	28.5	
mil USD	<14.9>	71	49.8%	9	<20.4>	<23.1>
				142	300	

7-4. Luitpold Pharmaceuticals, Inc. (US)

	FY2009 Results				FY2009 Forecast	
	Q1	Progress	YoY Changes	1st half	Full Year	
Luitpold Pharmaceuticals, Inc. (LPI)	<-1.1>	13.4	62.1%	-0.1	<-20.5>	<-14.9>
mil USD	<-6.2>	137	60.6%	8	<-11.2>	<-10.0>
Venofer <treatment for iron deficiency anemia>	<-3.9>	8.0	59.3%	-0.3	<-19.9>	<-14.2>
mil USD	<-3.2>	82	57.9%	3	<-10.5>	<-9.2>

7-5. Daiichi Sankyo Europe GmbH

	FY2009 Results				FY2009 Forecast	
	Q1	Progress	YoY Changes	1st half	Full Year	
Daiichi Sankyo Europe GmbH (DSE)	<-14.1>	17.3	50.2%	2.1	<-2.5>	<-1.0>
mil €	<-40.6>	131	45.4%	38	<-38.9>	<-20.8>
Olmotec / Olmetec Plus <antihypertensive>	<-0.2>	8.3	48.8%	0.0	<-8.9>	<-2.7>
mil €	<-23.0>	63	44.2%	12	<-23.6>	<-16.4>
Sevikar <antihypertensive>	<->	0.9	41.1%	0.9	<->	<-105.6>
mil €	<->	7	37.2%	7	<->	<-145.9>
Mevalotin <antihyperlipidemic agent>	<-11.3>	0.8	54.2%	0.1	<-24.0>	<-37.0>
mil €	<-37.2>	6	49.0%	2	<-3.0>	<-24.6>
Evista <treatment for osteoporosis>	<-24.9>	2.4	46.9%	-0.8	<-23.2>	<-12.4>
mil €	<-7.5>	18	42.5%	-1	<-4.1>	<-4.8>

Alliance Revenue of Efient (Europe)

	Q1	Progress	YoY Changes	
Efient <antiplatelet>	<->	0.0	-	0.0
mil USD	<->	0	-	0

* Alliance Revenue of Efient (Europe) is booked on Daiichi Sankyo Co., Ltd., thus, total sales of DSE above does not include such revenue.
Forecast of Efient is not disclosed.

7-6. Asia, South and Central America (ASCA)

	FY2009 Results			FY2009 Forecast		
	Q1	Progress	YoY Changes	1st half	Full Year	
ASCA Total	<0.5>	5.3	47.1%	0.0	<0.8>	<4.6>
Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. (DSBJ)	<-4.3>	1.0	48.0%	0.0	<-0.7>	<-5.6>
Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd. (DSSH)	<48.0>	1.1	45.1%	0.3	<43.2>	<26.3>
Daiichi Sankyo Korea Co., Ltd. (DSKR)	<-15.6>	0.8	52.5%	-0.1	<-19.9>	<8.4>
Daiichi Sankyo (Thailand) Ltd. (DSTH)	<-0.9>	0.2	39.4%	0.0	<4.0>	<4.9>
Daiichi Sankyo Taiwan Ltd. (DSTW)	<-8.6>	0.9	50.4%	-0.1	<-9.7>	<-4.2>
Daiichi Sankyo Brasil Farmacêutica Ltda. (DSBR)	<-25.5>	0.8	46.4%	-0.3	<-25.9>	<-22.0>
Daiichi Sankyo Venezuela, S.A. (DSVE)	<35.3>	0.7	42.2%	0.2	<45.9>	<45.5>

7-7. Ranbaxy Laboratories Limited

	FY2009 Results			FY2009 Forecast *	
	Q1	Progress	YoY Changes	Full Year	
Ranbaxy Laboratories Limited	<->	29.7	-	29.7	135.0
bil INR	<->	15.7	-	15.7	71.0

* Only full year forecasts are disclosed for Ranbaxy.

7-8. ASCA & Ranbaxy's Sales of Global Products

	FY2009 Results			FY2009 Forecast		
	Q1	Progress	YoY Changes	1st half	Full Year	
Olmesartan <antihypertensive>	<42.4>	1.8	60.8%	0.5	<-6.0>	<2.3>
Levofloxacin <synthetic antibacterial>	<-6.4>	1.8	48.7%	-0.1	<-4.2>	<-0.2>
Pravastatin <antihyperlipidemic>	<7.7>	0.8	54.7%	0.1	<-1.2>	<17.9>

8. Number of Employees

	FY2008		FY2009
	Jun-08	Mar-09	Jun-09*
Total Number of Employees	15,731	28,895	29,156
Japan	9,106	9,148	9,311
Overseas	6,625	19,747	19,845

	FY2008				FY2009	
	Jun-08	MRs	Mar-09	MRs	Jun-09*	MRs
Total Number of Employees	15,731		28,895		29,156	
<Japan>						
Daiichi Sankyo Co., Ltd. (DS)	6,024	2,400	5,960	2,400	6,057	2,400
Daiichi Sankyo Healthcare Co., Ltd (DSHC)	399	150	401	150	398	150
<US>						
Daiichi Sankyo, Inc. (DSI)	2,667	1,590	2,875	1,800	2,881	1,810
Luitpold Pharmaceuticals, Inc. (LPI)	495	90	477	70	488	70
<Europe>						
Daiichi Sankyo Europe GmbH (DSE)	1,774	850	2,436	1,350	2,472	1,360
<Asia / Latin America>						
Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. (DSBJ)	443	143	459	158	479	174
Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd. (DSSH)	476	196	504	208	533	229
Daiichi Sankyo Hong Kong Ltd. (DSHK)	7	-	7	-	7	-
Daiichi Sankyo Korea Co., Ltd. (DSKR)	89	49	98	49	98	49
Daiichi Sankyo (Thailand) Ltd. (DSTH)	43	17	44	18	42	16
Daiichi Sankyo Taiwan Ltd. (DSTW)	158	65	158	69	162	69
Daiichi Sankyo Brasil Farmacêutica Ltda. (DSBR)	266	118	292	112	313	118
Daiichi Sankyo Venezuela, S.A. (DSVE)	123	70	131	80	139	70

	FY2008		FY2009
	Jun-08	Mar-09	Jun-09*
Ranbaxy Group	-	12,174	12,131

* For overseas subsidiaries with different fiscal year-ends, figures as of Mar-09 are shown

9. Consolidated Balance Sheets

<Assets>

(Billions of yen)

	2009.3.31		2009.6.30		Change	Details
		%		%		
Current assets	783.5	52.4%	778.5	52.6%	-5.0	
Cash and time deposits	76.6		72.0		-4.5	Liquidity on hand (current deposits + marketable securities + investment securities) Total ¥349.8 billion (¥ -14.4 billion from the end of fiscal 2008)
Trade notes and accounts receivable	195.5		204.8		9.3	
Marketable securities	235.5		241.7		6.2	
Inventories	139.5		146.1		6.6	
Deferred tax assets	76.7		60.9		-15.9	
Other current assets	60.8		54.1		-6.7	
Allowance for doubtful accounts	-1.0		-1.1		-0.1	
Non-current assets	711.1	47.6%	702.6	47.4%	-8.5	
Property, plant and equipment	250.1	16.7%	249.9	16.9%	-0.2	
Buildings and structures	132.7		131.3		-1.4	
Machinery, equipment and vehicles	46.0		46.3		0.2	
Land	42.4		42.5		0.2	
Construction in progress	13.3		14.4		1.1	
Other	15.7		15.3		-0.3	
Intangible assets	192.6	12.9%	190.2	12.8%	-2.3	
Goodwill, net	77.4		75.2		-2.2	U3 Pharma: ¥ -1.3billion Ranbaxy: ¥ -0.6billion
Other intangible assets, net	115.2		115.0		-0.2	
Investments and other assets	268.4	18.0%	262.5	17.7%	-6.0	
Investment securities	153.7		153.6		-0.1	
Long-term loans	0.6		0.4		-0.2	
Prepaid pension costs	6.9		6.0		-0.9	
Deferred tax assets	91.6		86.8		-4.8	
Other assets	15.9		15.9		0.1	
Allowance for doubtful accounts	-0.3		-0.3		0.0	
Total assets	1,494.6	100.0%	1,481.1	100.0%	-13.5	

<Liabilities and Net Assets>

(Billions of yen)

	2009.3.31		2009.6.30		Change	Details
		%		%		
Liabilities	606.0	40.5%	626.4	42.3%	20.4	
Current liabilities	508.5	34.0%	428.4	28.9%	-80.2	
Trade notes and accounts payable	59.4		59.1		-0.3	
Short-term bank loans	264.3		167.8		-96.6	Change to long-term financing by the issuance of bonds
Income taxes payable	8.2		9.8		1.6	
Allowance for sales returns	0.6		0.6		0.1	
Allowance for sales rebates	2.7		2.5		-0.2	
Other current liabilities	173.3		188.5		15.2	Valuation loss on derivatives of Ranbaxy, etc.
Long-term liabilities	97.4	6.5%	198.0	13.4%	100.6	
Bonds payable	-		100.0		100.0	1st Series of Unsecured Straight Bonds; ¥ 60 billion yen Maturity: 5 years, Interest rate: 1.078% per annum
Convertible bond-type bonds with subscription rights to shares	47.1		50.4		3.4	2nd Series of Unsecured Straight Bonds; ¥ 40 billion Maturity: 10 years, Interest rate: 1.776% per annum
Long-term bank loans	15.9		15.6		-0.2	
Deferred tax liabilities	5.4		5.6		0.1	
Accrued employees' severance and retirement benefits	10.6		11.1		0.5	
Accrued directors' severance and retirement benefits	0.2		0.2		0.0	
Provision for environmental measures	0.1		0.0		-0.1	
Other long-term liabilities	18.2		15.1		-3.1	
Net assets	888.6	59.5%	854.7	57.7%	-33.9	
Shareholders' equity	894.5	59.8%	859.9	58.1%	-34.6	
Common stock	50.0		50.0		0.0	
Capital surplus	105.2		105.2		0.0	
Retained earnings	753.8		719.2		-34.6	Dividends paid ¥ -28.2 billion (year-end dividend ¥40) Net income ¥ -6.4 billion
Treasury stock at cost	-14.6		-14.6		0.0	
Valuation and other adjustments	-31.4	-2.1%	-22.3	-1.5%	9.1	
Net unrealized gain on investment securities	19.9		27.7		7.8	
Deferred gains or losses on hedges	0.1		0.1		0.0	
Foreign currency translation adjustments	-51.4		-50.1		1.2	
Subscription rights to shares	2.4	0.2%	2.6	0.2%	0.2	
Minority interests	23.2	1.6%	14.6	1.0%	-8.6	
Total liabilities and net assets	1,494.6	100.0%	1,481.1	100.0%	-13.5	

10. Consolidated Statements of Cash Flows

(Billions of yen)

	FY2008 Q1	FY2009 Q1	Change	Details
Income before income taxes and minority interests	39.5	8.6	-30.9	
Depreciation	9.5	10.6	1.1	
Amortization of goodwill	0.8	2.2	1.3	
Loss on valuation of derivatives	-	12.8	12.8	
(Gain) loss on sales of investments securities	-0.0	-1.8	-1.8	
(Increase) decrease in trade notes and accounts receivable	-12.3	-8.5	3.8	
(Increase) decrease in inventories	-0.0	-5.9	-5.9	
Increase (decrease) in trade notes and accounts payable	-5.7	-0.8	4.8	
Increase (decrease) in accounts payable and accrued expenses	-3.2	-1.8	1.4	
Other, net	-0.5	5.1	5.5	
Income taxes paid	-20.3	-2.6	17.7	
Cash flows from operating activities	7.9	17.7	9.8	
Net (increase) decrease in short-term operating assets	12.5	23.5	11.0	
(Acquisitions) / proceeds from sales of fixed assets	-4.7	-5.8	-1.1	
(Acquisitions) / proceeds from sales of investment securities	-26.7	3.1	29.8	--- FY2008: Provisional payment of tender offer on Ranbaxy shares, etc.
Purchases of investments in consolidated subsidiaries	-24.3	-	24.3	--- FY2008: Acquisition of U3 Pharma
Other, net	1.0	0.1	-0.9	
Cash flows from investing activities	-42.2	20.9	63.1	
Net increase (decrease) in short-term bank loans and long-term debt	-0.1	-97.2	-97.2	--- Decrease in short-term bank loans by the issuance of bonds
Proceeds from issuance of bonds	-	99.7	99.7	--- Issuance of unsecured straight bonds (net of issue cost)
Dividends paid	-25.2	-28.2	-3.0	--- Dividend increase of 5 yen per share
Other, net	-0.0	-0.1	0.0	
Cash flows from financing activities	-25.2	-25.8	-0.5	
Effect of exchange rate changes on cash and cash equivalents	2.8	0.2	-2.6	
Net increase (decrease) in cash and cash equivalents	-56.7	13.0	69.7	
Cash and cash equivalents, beginning of year	444.3	177.8	-266.6	
Cash and cash equivalents, end of year	387.6	190.8	-196.8	

(This page is intentionally left blank)

11. Major R&D Pipeline

Daiichi Sankyo Group Major Research & Development Pipeline (Development Stage)

Therapeutic Area	Main Existing Product	Phase1	Phase2
Cardiovascular diseases	Mevalotin Benicar/Olmetec Azor/Sevikar Welchol Olmetec Calblock Artist Mevalotin Kremezin Hanp Livalo Sunrythm Bepricor	DB-772d(US/EU) (oral factor Xa inhibitor)	☆CS-866CMB(JP) (Olmesartan/Hydrochlorothiazide combination) DU-176b(US/EU) (Edoxaban/venous thromboembolism/oral factor Xa inhibitor) CS-747(JP) (Prasugrel/anti-platelet agent)
Glucose metabolic disorders	Welchol Fastic	CS-1036(JP/Asia) (glucose absorption inhibitor)	CS-011(JP) (Rivoglitazone/ glitazone agent that improves insulin resistance)
Infectious diseases	Levaquin / Tavanic Banan Cravit	CS-8958(US/EU) (Laninamivir/anti-influenza/co-development with Biota)	
Cancer	Topotecin Krestin	U3-1287(US) (anti-HER3 antibody) CS-1008(JP) (Tigatuzumab/anti-DR5 antibody)	CS-1008(US) (Tigatuzumab/anti-DR5 antibody) CS-7017(US) (PPARγ activator) DE-766(JP) (Nimotuzumab/anti-EGFR antibody) ARQ 197(US/EU) (c-Met inhibitor)
Immunological allergic diseases	Zyrtec	CS-0777(US/EU) (immunomodulator)	SUN13834(US) (chymase inhibitor)
Bone/Joint diseases	Loxonin Mobic		
Others	Venofor Evoxac Omnipaque Omniscan Visipaque Sonazoid Feron Urief		SUN11031(US/EU) (Human ghrelin/cachexia) ☆DD-723-B(JP) (Perflubutane/ultrasonic contrast agent)


☆Additional indications, new formulations etc.

Change from the announcement in May 2009

New(underline)

Change of Stage etc. CS-747(US/ACS-PCI/approved), CS-600G(JP/application)

Withdrawal of Development etc. CS-011(JP/US/EU) [Result of a clinical trial was not sufficient enough to differentiate this project from existing product.]
CS-866DM(JP) [Result of a clinical trial did not satisfy the primary endpoint criteria.]

Phase3	Application
<p>☆CS-747(US/EU) (Prasugrel/ACS-MM/anti-platelet agent)</p> <p>☆CS-866DM(JP) (Olmesartan/diabetic nephropathy)</p> <p>DU-176b(US/EU/JP/Asia) (Edoxaban/atrial fibrillation/oral factor Xa inhibitor)</p> <p>DU-176b(JP) (Edoxaban/venous thromboembolism/oral factor Xa inhibitor)</p> <p>☆CS-8635(US/EU) (Olmesartan/Amlodipine/Hydrochlorothiazide combination)</p>	<p>CS-747(US) (Prasugrel/ACS-PCI/anti-platelet agent/approved)</p> <p>☆CS-866AZ(JP) (Olmesartan/Azelinidipine combination)</p>
<p>CS-044(US/EU) (Rivoglitazone/ glitazone agent that improves insulin resistance)</p>	
<p>☆Levofloxacin inj(JP) (new quinolone)</p> <p>CS-8958(JP) (Laninamivir/anti-influenza)</p>	
<p>AMG 162(JP) (Denosumab/bone metastases of cancer, osteoporosis/ anti-RANKL antibody)</p> 	<p>☆CS-600G(JP) (Loxoprofen/gel)</p>
<p>SUN11031(JP) (Human ghrelin/anorexia nervosa)</p> <p>SUN Y7017(JP) (Memantine/mild to moderate and severe dementia of Alzheimer type)</p>	<p>☆DL-8234(JP) (FERON add indic./hepatitis C/with Ribavirin)</p> <p>KMD-3213(China) (Silodosin/treatment of dysuria associated with benign prostatic hyperplasia)</p>

1. Summary of Income Statement

(Billions of yen)

	FY2008										FY2009	
	Q1		Q2		Q3		Q4		Full Year		Q1	
Net sales	<-13.5> 100.0	203.7	<-2.7> 100.0	202.6	<-12.2> 100.0	221.3	<-16.4> 100.0	214.5	<-4.3> 100.0	842.1	<-11.5> 100.0	227.1
Cost of sales	23.9	48.6	24.2	49.0	24.0	53.1	29.7	63.6	25.5	214.4	27.5	62.5
Selling, general and administrative expenses	56.5	115.1	65.1	132.0	59.5	131.7	74.6	160.1	64.0	538.9	60.7	137.8
Research and development expenses	18.1	36.9	22.4	45.4	21.2	46.8	25.8	55.4	21.9	184.5	19.9	45.1
Other expenses	38.4	78.2	42.7	86.6	38.4	84.9	48.8	104.7	42.1	354.3	40.8	92.7
Operating income	<-41.0> 19.6	40.0	<-17.1> 10.7	21.6	<-42.0> 16.5	36.4	<-> -	-9.2	<-43.3> 10.6	88.9	<-33.1> 11.8	26.8
Non-operating income		3.6		2.5		3.0		3.1		12.3		3.9
Non-operating expenses		2.8		5.3		5.9		31.9		46.0		23.5
Ordinary income	<-43.0> 20.1	40.9	<-35.3> 9.3	18.8	<-48.7> 15.2	33.5	<-> -	-38.0	<-67.4> 6.6	55.2	<-82.5> 3.2	7.2
Extraordinary gains		0.0		0.8		1.8		1.1		3.8		2.1
Extraordinary losses		1.3		2.6		357.4		5.9		367.2		0.7
Income before income taxes and minority interests	19.4	39.5	8.4	17.0	-	-322.0	-	-42.8	-	-308.3	3.8	8.6
Net income	<-39.4> 12.3	25.1	<-52.8> 4.4	8.9	<-> -	-331.8	<-> 38.4	82.3	<-> -	-215.5	<-> -	-6.4

2. Currency Rate

	FY2008				FY2009	
	Q1	Q2 YTD	Q3 YTD	Full Year		Q1
Yen / USD (average)	104.6	106.1	102.8	100.5		97.3
Yen / EUR (average)	163.4	162.7	150.7	143.5		132.6
Yen / INR (average)	-	-	-	2.00		1.89

3. Sales of Global Products

(Billions of yen)

	FY2008					FY2009	
	Q1	Q2	Q3	Q4	Full Year		Q1
Olmесartan <antihypertensive>	<-4.5> 50.7	<-23.7> 53.9	<-6.6> 57.6	<-9.1> 49.0	<-8.0> 211.1	<-10.5> 56.0	
Olmotec (JPN)	<-12.8> 15.6	<-24.9> 15.7	<-6.0> 18.7	<-28.7> 14.4	<-16.6> 64.4	<-22.1> 19.0	
Benicar / Benicar HCT (US)	<-2.6> 23.4	<-1.8> 22.1	<-7.5> 22.3	<-1.6> 19.6	<-0.6> 87.4	<-5.6> 22.1	
Azor (US)	<-> 1.4	<-> 2.4	<-39.6> 2.6	<-241.8> 2.3	<-240.7> 8.7	<-121.5> 3.0	
Olmotec / Olmetec Plus* (EU)	<-44.3> 8.3	<-40.7> 10.3	<-10.1> 9.1	<-13.6> 9.7	<-10.3> 37.5	<-0.2> 8.3	
Sevikar (EU)	- -	- -	- 1.4	<-> 0.8	<-> 2.2	<-> 0.9	
Other subsidiaries / Export, etc	<-30.4> 2.0	<-72.2> 3.3	<-62.0> 3.5	<-12.5> 2.2	<-35.6> 11.0	<-29.9> 2.6	
Levofloxacin <synthetic antibacterial>	<-12.6> 25.8	<-0.5> 23.6	<-19.8> 25.8	<-4.6> 22.6	<-10.2> 97.7	<-23.2> 19.8	
Cravit (JPN)	<-15.5> 10.2	<-6.0> 9.4	<-11.5> 13.7	<-1.2> 9.7	<-9.2> 43.0	<-6.8> 9.5	
Export, etc	<-11.3> 9.6	<-19.4> 8.3	<-36.8> 6.2	<-7.6> 7.1	<-8.7> 31.1	<-49.6> 4.8	
Royalty	<-12.6> 4.1	<-13.8> 4.0	<-15.9> 4.1	<-26.6> 4.0	<-17.6> 16.1	<-9.9> 3.7	
Other subsidiaries	<-1.8> 1.9	<-0.9> 1.9	<-11.9> 1.8	<-2.6> 1.8	<-4.0> 7.5	<-6.4> 1.8	
Pravastatin <antihyperlipidemic>	<-25.8> 16.1	<-14.9> 15.9	<-23.3> 16.6	<-15.3> 12.3	<-20.5> 60.8	<-8.5> 14.7	
Mevalotin (JPN)	<-17.1> 13.5	<-14.8> 13.1	<-22.6> 14.1	<-14.3> 10.0	<-17.6> 50.7	<-8.3> 12.4	
Export	<-39.0> 1.0	<-33.6> 0.8	<-54.0> 0.6	<-3.5> 0.7	<-36.6> 3.2	<-37.6> 0.7	
European subsidiaries*	<-74.3> 0.7	<-3.4> 1.2	<-1.2> 1.2	<-43.9> 0.7	<-40.7> 4.0	<-11.3> 0.8	
Other subsidiaries	<-3.1> 0.8	<-7.6> 0.8	<-25.4> 0.6	<-7.1> 0.9	<-7.2> 3.0	<-7.7> 0.8	

* The accounting period of Daiichi Sankyo Europe GmbH (DSE) was 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March. Three months results of Olmetec / Olmetec Plus and Pravastatin from Jan-07 to Mar-07 were ¥6.4 billion (€40 million) and ¥1.6 billion (€10 million), respectively.

4. Overseas Sales

(Billions of yen)

	FY2008					FY2009
	Q1	Q2	Q3	Q4	Full Year	Q1
Overseas sales	<-15.9> 88.7	<-3.6> 86.1	<-9.3> 83.8	<-47.5> 114.7	<-4.1> 373.3	<-23.9> 109.8
Overseas sales ratio	43.5%	42.5%	37.9%	53.5%	44.3%	48.4%
North America	<-3.9> 58.3	<-2.7> 53.6	<-15.1> 52.8	<-21.7> 56.6	<-0.6> 221.3	<-1.1> 58.9
Europe*	<-42.6> 22.4	<-31.8> 23.3	<-12.9> 21.9	<-37.0> 30.5	<-0.3> 98.2	<-21.3> 27.2
Other	<-22.3> 8.0	<-10.9> 9.2	<-15.4> 9.1	<-206.7> 27.6	<-33.6> 53.8	<-197.4> 23.7

* The accounting period of Daiichi Sankyo Europe GmbH (DSE) was 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March. The net sales of DSE for the period from January to March 2007 was ¥14.1 billion.

5. Consolidated Segment information - Operating Segment

(Billions of yen)

	FY2008					FY2009
	Q1	Q2	Q3	Q4	Full Year	Q1
Net Sales	<-13.5> 203.7	<-2.7> 202.6	<-12.2> 221.3	<-16.4> 214.5	<-4.3> 842.1	<-11.5> 227.1
Pharmaceuticals	<-10.2> 202.9	<-1.7> 201.6	<-8.6> 220.5	<-21.7> 213.7	<-0.2> 838.7	<-11.5> 226.3
Domestic	<-8.2> 103.3	<-0.4> 101.6	<-9.3> 123.2	<-1.8> 88.6	<-4.7> 416.7	<-3.1> 106.6
Overseas*	<-14.1> 88.7	<-5.3> 85.8	<-6.1> 84.0	<-46.7> 114.9	<-5.9> 373.3	<-23.9> 109.9
OTC drugs	<-3.1> 10.2	<-5.2> 13.8	<-13.2> 13.2	<-6.5> 10.1	<-6.2> 47.2	<-6.9> 9.5
Other	<-91.5> 0.8	<-90.0> 1.0	<-93.0> 0.8	<-90.7> 0.8	<-91.3> 3.4	<-2.6> 0.8
Operating income	<-41.0> 40.0	<-17.1> 21.6	<-42.0> 36.4	<-> -9.2	<-43.3> 88.9	<-33.1> 26.8
Pharmaceuticals	<-42.3> 39.4	<-18.9> 20.9	<-42.5> 35.9	<-> -9.7	<-44.3> 86.6	<-33.5> 26.2
Other	<-> 0.5	<-> 0.7	46 0.5	-54 0.5	<-116.2> 2.2	<-1.3> 0.5

* The accounting period of Daiichi Sankyo Europe GmbH (DSE) was 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March. The operating results of DSE for the period from January to March 2007 was net sales of ¥14.1 billion and operating income of ¥1.8 billion.

6. Consolidated Segment information - Geographic Segment

(Billions of yen)

	FY2008					FY2009
	Q1	Q2	Q3	Q4	Full Year	Q1
Net Sales	<-13.5> 203.7	<-2.7> 202.6	<-12.2> 221.3	<-16.4> 214.5	<-4.3> 842.1	<-11.5> 227.1
Japan	<-12.6> 132.7	<-7.3> 133.0	<-15.8> 151.4	<-8.4> 112.7	<-11.4> 529.8	<-3.1> 128.5
North America	<-12.5> 50.7	<-1.4> 45.3	<-10.0> 46.0	<-31.7> 48.9	<-7.2> 190.8	<-7.0> 54.2
Europe*	<-53.1> 15.2	<-41.9> 18.5	<-24.8> 18.0	<-41.8> 25.8	<-0.7> 77.4	<-48.1> 22.5
India	- -	- -	- -	<-> 15.3	<-> 15.3	<-> 11.5
Other	<-16.9> 5.2	<-16.3> 5.8	<-13.9> 5.9	<-101.4> 11.9	<-10.9> 28.9	<-99.7> 10.5
Operating income	<-41.0> 40.0	<-17.1> 21.6	<-42.0> 36.4	<-> -9.2	<-43.3> 88.9	<-33.1> 26.8
Japan	18.5	8.2	25.5	-8.8	43.4	15.6
North America	16.9	10.9	11.6	10.9	50.3	13.9
Europe*	1.2	0.0	0.5	4.0	5.8	1.2
India	-	-	-	-18.9	-18.9	-3.2
Other	0.7	0.4	-3.5	2.7	0.4	0.9

* The accounting period of Daiichi Sankyo Europe GmbH (DSE) was 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March. The operating results of DSE for the period from January to March 2007 was net sales of ¥14.1 billion and operating income of ¥1.8 billion.

7. Status of Major Companies

Data available at www.daiichisankyo.com/ir/financial/index.html

7-1. Daiichi Sankyo Co., Ltd.

(Billions of yen)

	FY2008					FY2009
	Q1	Q2	Q3	Q4	Full Year	Q1
Total net sales of ethical pharmaceuticals	<-8.8> 100.9	<-0.9> 99.5	<-8.9> 120.1	<2.3> 86.2	<-4.8> 406.7	<3.7> 104.6
Cardiovascular disease	<-5.9> 60.0	<-2.2> 57.2	<-8.8> 65.5	<-0.6> 49.9	<-4.8> 232.5	<3.8> 62.3
Olmotec <antihypertensive>	<12.8> 15.6	<24.9> 15.7	<6.0> 18.7	<28.7> 14.4	<16.6> 64.4	<22.1> 19.0
Calblock <antihypertensive>	<19.4> 3.0	<26.9> 2.9	<13.6> 3.4	<17.2> 2.8	<18.9> 12.1	<14.5> 3.5
Artist <antihypertensive>	<3.3> 5.7	<4.9> 5.3	<0.5> 6.0	<6.8> 4.9	<3.6> 21.9	<6.3> 6.0
Mevalotin <antihyperlipidemic agent>	<-17.1> 13.5	<-14.8> 13.1	<-22.6> 14.1	<-14.3> 10.0	<-17.6> 50.7	<-8.3> 12.4
Kremezin <treatment for chronic renal failure>	<3.9> 3.2	<3.9> 3.2	<-0.5> 3.5	<5.3> 2.8	<2.9> 12.8	<5.5> 3.4
Hanp <treatment for acute cardiac failure>	<-7.8> 2.4	<-3.2> 1.8	<-5.2> 2.8	<-8.1> 2.2	<-6.2> 9.2	<1.5> 2.4
Livalo <antihyperlipidemic agent>	<10.0> 1.5	<13.8> 1.5	<8.1> 1.8	<16.6> 1.4	<11.8> 6.1	<22.8> 1.8
Sunrythm <antiarrhythmic agent>	<-4.2> 3.1	<-2.9> 2.9	<-6.1> 3.2	<-0.3> 2.5	<-3.6> 11.6	<-1.2> 3.0
Fastic <antidiabetic agent>	<-0.5> 1.3	<-0.1> 1.3	<-2.9> 1.4	<-1.3> 1.1	<-1.2> 5.1	<1.8> 1.4
Infectious diseases / bone and joint diseases / immunological allergic diseases / urology	<-8.3> 30.8	<4.2> 31.9	<-2.6> 44.7	<4.6> 30.0	<-1.0> 137.4	<-9.4> 33.7
Cravit <synthetic antibacterial agent>	<-15.5> 10.2	<-6.0> 9.4	<-11.5> 13.7	<-1.2> 9.7	<-9.2> 43.0	<-6.8> 9.5
Loxonin <anti-inflammatory analgesic>	<2.2> 8.4	<28.3> 10.4	<17.1> 11.5	<12.3> 8.3	<15.1> 38.7	<33.0> 11.2
Mobic <anti-inflammatory analgesic>	<-13.1> 2.4	<-16.7> 2.1	<-23.1> 2.2	<-18.3> 1.6	<-17.8> 8.4	<-17.5> 2.0
Urief <treatment for dysuria>	<59.7> 1.8	<45.4> 1.8	<25.9> 2.1	<60.5> 2.2	<46.0> 7.9	<26.6> 2.2
Zyrtec <antiallergic agent>	<-23.8> 2.0	<-16.1> 1.6	<-15.6> 2.2	<-4.8> 3.5	<-14.1> 9.3	<18.4> 2.4
Contrast agents / cancer / gastric diseases	<-22.2> 12.3	<-13.6> 12.5	<-19.0> 13.9	<-13.6> 10.1	<-17.5> 48.8	<-2.9> 12.6
Omnipaque <contrast agent>	<-11.3> 7.3	<-5.4> 7.3	<-13.2> 8.0	<-4.7> 5.7	<-9.1> 28.3	<-2.0> 7.1
Topotecin <anticancer agent>	<0.7> 1.6	<2.1> 1.5	<-1.0> 1.7	<2.1> 1.4	<0.9> 6.2	<5.6> 1.7

7-2. Daiichi Sankyo Healthcare Co., Ltd

(Billions of yen)

	FY2008					FY2009
	Q1	Q2	Q3	Q4	Full Year	Q1
Daiichi Sankyo Healthcare Co., Ltd	<3.1> 10.2	<-5.2> 13.8	<-13.2> 13.2	<-6.5> 10.1	<-6.2> 47.2	<-6.9> 9.5
LuLu Series	<8.7> 1.2	<-2.0> 3.6	<-4.0> 3.5	<-6.9> 1.4	<-2.2> 9.8	<-2.4> 1.2
Gaster 10	<-15.5> 0.7	<7.8> 0.9	<-2.6> 1.0	<-12.6> 0.7	<-5.5> 3.3	<-29.1> 0.5
Shin-Sankyo Ichoyaku series	<7.9> 0.7	<31.2> 0.9	<-26.4> 1.0	<-12.1> 0.7	<-5.2> 3.3	<26.3> 0.9
Patecs series	<-19.5> 0.8	<-9.0> 0.8	<0.0> 0.7	<-9.3> 0.4	<-10.4> 2.7	<15.3> 0.9
Transino	<-> 0.7	<-62.0> 0.5	<-76.9> 0.2	<-69.6> 0.1	<-41.4> 1.5	<-62.3> 0.3

7-3. Daiichi Sankyo, Inc. (US)

(Billions of yen)

	FY2008					FY2009	
	Q1	Q2	Q3	Q4	Full Year	Q1	
Daiichi Sankyo, Inc. (DSI)	<12.0>	<-0.6>	<-13.5>	<-15.3>	<-1.9>	<-11.2>	33.0
mil USD	<29.4>	<-8.4>	<-2.1>	<-27.9>	<-15.8>	<-4.6>	339
	37.2	31.7	32.6	27.9	129.3		
	356	294	337	300	1,286		
Benicar / Benicar HCT <antihypertensive>	<2.6>	<-1.8>	<-7.5>	<-1.6>	<-0.6>	<-5.6>	22.1
mil USD	<18.6>	<-11.3>	<-8.7>	<-14.1>	<-13.0>	<-1.4>	227
	223	205	230	210	869		
Azor <antihypertensive>	<->	<->	<-39.6>	<-241.8>	<-240.7>	<-121.5>	3.0
mil USD	<->	<->	<-66.2>	<-285.1>	<-287.2>	<-138.0>	31
	1.4	2.4	2.6	2.3	8.7		
	13	23	27	24	86		
Welchol <antihyperlipidemic / type 2 diabetes>	<-11.0>	<-8.8>	<-6.6>	<-4.3>	<-7.8>	<-7.0>	6.9
mil USD	<-28.2>	<-18.9>	<-24.7>	<-17.8>	<-22.5>	<-14.9>	71
	6.4	6.1	6.6	5.3	24.5		
	62	57	68	57	244		

7-4. Luitpold Pharmaceuticals, Inc. (US)

(Billions of yen)

	FY2008					FY2009	
	Q1	Q2	Q3	Q4	Full Year	Q1	
Luitpold Pharmaceuticals, Inc. (LPI)	<13.8>	<-6.4>	<-0.5>	<-17.8>	<-0.1>	<-1.1>	13.4
mil USD	<31.4>	<-16.5>	<-16.9>	<-5.7>	<-13.8>	<-6.2>	137
	13.5	13.5	13.4	10.7	51.1		
	129	126	139	115	509		
Venofor <treatment for iron deficiency anemia>	<23.1>	<-6.4>	<-1.7>	<-15.3>	<-3.1>	<-3.9>	8.0
mil USD	<42.2>	<-16.7>	<-19.5>	<-2.8>	<-17.2>	<-3.2>	82
	8.3	8.5	8.3	6.9	32.0		
	80	79	86	74	319		

7-5. Daiichi Sankyo Europe GmbH

(Billions of yen)

	FY2008					FY2009	
	Q1	Q2	Q3	Q4	Full Year	Q1	
Daiichi Sankyo Europe GmbH (DSE)	<-53.1>	<-42.4>	<-24.2>	<-2.4>	<-9.9>	<-14.1>	17.3
mil €	<-54.2>	<-42.5>	<-53.8>	<-27.9>	<-0.8>	<-40.6>	131
	15.2	18.5	18.0	18.6	70.3		
	93	114	136	147	490		
Olmotec / Olmetec Plus <antihypertensive>	<-44.3>	<-40.7>	<-10.1>	<-13.6>	<-10.3>	<-0.2>	8.3
mil €	<-45.6>	<-40.5>	<-37.5>	<-8.5>	<-0.3>	<-23.0>	63
	8.3	10.3	9.1	9.7	37.5		
	51	64	70	77	261		
Sevikar <antihypertensive>	<->	<->	<->	<->	<->	<->	0.9
mil €	<->	<->	<->	<->	<->	<->	7
	-	-	1.4	0.8	2.2		
	-	-	9	6	15		
Mevalotin <antihyperlipidemic agent>	<-74.3>	<-3.4>	<-1.2>	<-43.9>	<-40.7>	<-11.3>	0.8
mil €	<-74.9>	<-3.6>	<-23.3>	<-25.7>	<-33.7>	<-37.2>	6
	0.7	1.2	1.2	0.7	4.0		
	4	8	9	6	28		
Evista <treatment for osteoporosis>	<-71.7>	<-419.7>	<-134.5>	<-57.8>	<-128.5>	<-24.9>	2.4
mil €	<-67.7>	<-421.3>	<-195.4>	<-111.8>	<-155.6>	<-7.5>	18
	3.2	3.5	3.0	2.2	12.0		
	20	22	23	18	84		

* Following the change in fiscal year-end, FY2007 results for DSE, Olmetec / Olmetec Plus, Mevalotin and Evista are fifteen-months totals from Jan-07 to Mar-08.

Three months results from Jan-07 to Mar-07 were ¥14.1 billion (€89 million), ¥6.4 billion (€40 million), ¥1.6 billion (€10 million), and ¥1.0 billion (€6 million), respectively.

Alliance Revenue of Efient (Europe)

Efient <antiplatelet>	-	-	-	<->	<->	<->
mil USD	-	-	-	<->	<->	<->
				0.03	0.03	0.0
				0.3	0.3	0

* Alliance Revenue of Efient (Europe) is booked on Daiichi Sankyo Co., Ltd., thus, total sales of DSE above does not include Alliance Revenue of Efient (Europe).

7-6. Asia, South and Central America (ASCA)

(Billions of yen)

	FY2008					FY2009	
	Q1	Q2	Q3	Q4	Full Year	Q1	
ASCA Total	<10.5>	<12.7>	<14.3>	<1.6>	<9.5>	<0.5>	5.3
	5.2	5.8	5.9	6.0	23.0		
Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. (DSBJ)	<10.9>	<-0.8>	<11.4>	<-22.0>	<-1.3>	<-4.3>	1.0
	1.0	1.0	1.1	0.9	4.0		
Daiichi Sankyo Pharmaceutical(Shanghai) Co., Ltd. (DSSH)	<29.5>	<64.3>	<62.4>	<126.2>	<69.0>	<48.0>	1.1
	0.7	0.9	1.1	1.1	3.8		
Daiichi Sankyo Korea Co., Ltd. (DSKR)	<4.3>	<1.1>	<-35.5>	<-19.7>	<-12.4>	<-15.6>	0.8
	0.9	0.9	0.6	0.6	3.0		
Daiichi Sankyo (Thailand) Ltd. (DSTH)	<-4.9>	<17.9>	<-3.3>	<-13.4>	<-1.4>	<-0.9>	0.2
	0.2	0.2	0.2	0.2	0.8		
Daiichi Sankyo Taiwan Ltd. (DSTW)	<1.6>	<1.2>	<-9.0>	<-15.5>	<-5.4>	<-8.6>	0.9
	0.9	1.0	0.8	0.8	3.5		
Daiichi Sankyo Brasil Farmacéutica Ltda. (DSBR)	<11.5>	<14.9>	<38.7>	<-4.2>	<13.6>	<-25.5>	0.8
	1.0	1.2	1.4	1.4	5.0		
Daiichi Sankyo Venezuela, S.A. (DSVE)	<21.7>	<12.0>	<40.5>	<9.8>	<19.0>	<35.3>	0.7
	0.5	0.6	0.7	1.0	2.8		

7-7. Ranbaxy Laboratories Limited

(Billions of yen)

	FY2008					FY2009	
	Q1	Q2	Q3	Q4	Full Year	Q1	
Ranbaxy Laboratories Limited				<>	<>	<>	29.7
	-	-	-	38.6	38.6		
bil INR	-	-	-	<>	<>	<>	15.7
	-	-	-	19.3	19.3		

7-8. ASCA & Ranbaxy's Sales of Global Products

(Billions of yen)

	FY2008					FY2009	
	Q1	Q2	Q3	Q4	Full Year	Q1	
Olmесartan <antihypertensive>	<69.3>	<110.1>	<98.0>	<38.4>	<74.2>	<42.4>	1.8
	1.3	1.9	2.1	2.1	7.3		
Levofloxacin <synthetic antibacterial>	<-1.8>	<0.9>	<-11.9>	<-2.6>	<-4.0>	<-6.4>	1.8
	1.9	1.9	1.8	1.8	7.5		
Pravastatin <antihyperlipidemic>	<-3.1>	<-7.6>	<-25.4>	<7.1>	<-7.2>	<7.7>	0.8
	0.8	0.8	0.6	0.9	3.0		

(This page is intentionally left blank)

